Paper - WANFANG MED ONLINE

You Position: Home > Paper

Intraocular antiangiogenic drugs in clinical application advantages and disadvantages

( views:1100, downloads:1972 )

Author:: No author available

Journal Title:: Chinese Journal of Ophthalmology

Issue:: 10

DOI:: 10.3760/cma.j.issn.0412-4081.2012.10.003

Key Word:: 视网膜新生血管化;新生血管化,病理性;血管生成抑制剂;血管内皮生长因子A;Retinal neovascularization;Neovascularization pathologic;Angiogenesis inhibitors;Vascular endothelial growth factor A

Abstract： Many retinal vascular diseases have all been shown to share the upregulation of VEGF expression of vascular endothelial growth factor (VEGF) in the pathologies,recent clinical trials regarding the intravitreal injection of anti-VEGF agents have shown a shrink of CNV and decreased leakage.Certain efficacy was shown in the treatment of angiogenic pathologies including neovascular AMD,choroidal neovascularization caused by several different causes,macular edema by diabetic retinopathy and vein occlusion,Retinopathy of prematurity,and neovascular glaucoma.A controversies in the indication of treatment using anti-VEGF are:inhibit the new vessels of proliferative diabetic retinopathy? decreased bleeding using intravitreal bevacizumab before vitrectomy of diabetic retinopathy? reduced leaking in Coats Diseases? The controversy based on a new finding of fibrosis formation after using intravitreal anti-VEGF.however,recurrent/persistent leaking from CNV or macular edema is common,there is a potential risk of endophthalmitis for frequently intravitreal injections.

Reference

[1]The Branch Vein Occlusion Study Group.Argon Laser Photocoagulation for Macular Edema in Branch Vein Occlusion[J].1984,98(3).
[2]Williams G,Di-Bartolo E,Miniaci S,etc.Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).[J].2008,246(6).
[3]Adamis AP,Feinsod M,Guyer DR,etc.Pegaptanib for neovascular age-related macular degeneration.[J].2004,351(27).
[4]Grunwald JE,Fine SL,Maguire MG,etc.Ranibizumab and bevacizumab for neovascular age-related macular degeneration.[J].2011,364(20).
[5]Zhu W,Luo D,Zhang M,etc.A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.[J].2011,118(4).
[6]Saroj N,Brown DM,Awh CC,etc.Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.[J].2011,118(10).
[7]Lanzetta,P.,Tokaji,E.,Pilz,S.,etc.Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results[J].2012,119(5).
[8]Marcus D,Berliner AJ,Vitti R,etc.The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.[J].2011,118(6).
[9]L P, Aiello,R L, Avery,P G, Arrigg,etc.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.[J].1994,331(22).
[10]VanGeest,R.J.,Lesnik-Oberstein,S.Y.,Tan,H.S.,etc.A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J].2012,96(4).
[11]Kennedy KA,Chuang AZ,Mintz Hittner HA.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.[J].2011,364(7).
[12]Schraermeyer U,Bartz-Schmidt KU,Julien S,etc.Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye.[J].2008,92(4).
[13]Bandello F,Larsen M,Weichselberger A,etc.Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.[J].2010,33(11).
[14]Li,X.,Hu,Y.,Sun,X.,etc.Bevacizumab for neovascular age-related macular degeneration in China[J].2012,119(10).
[15]Sutter F,Gerstner O,Burian G,etc.The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.[J].2011,118(4).
[16]Xiaoying Liang,Xiaoxin Li,Kai Wang,etc.Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy[J].2009,87(7).
[17]Brown DM,Chung CY,Kim RY,etc.Ranibizumab for neovascular age-related macular degeneration.[J].2006,355(14).
[18]Moradian S,Ahmadieh H,Malihi M,etc.Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.[J].2008,246(12).
[19]Shields,C.L.,Ramasubramanian,A..Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction[J].2012,96(3).
[20]Stassen JM,Van Bergen T,Vandewalle E,etc.The role of different VEGF isoforms in scar formation after glaucoma filtration surgery.[J].2011,93(5).
[21]Do DV,Shah SM,Quinlan EJ,etc.RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.[J].2010,150(1).
[22]Schmidinger G,Maar N,Bolz M,etc.Repeated intravitreal bevacizumab (Avastin((R))) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.[J].2011,89(1).
[23]Mark Michels,David M.Brown,eter K.Kaiser.Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study[J].2009,116(1).
[24]Pe'er J,Hemo I,Keshet E,etc.Vascular endothelial growth factor upregulation in human central retinal vein occlusion.[J].1998,105(3).
[25]Saroj N,Ho AC,Murahashi WY,etc.Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.[J].2011,118(8).